XSHG
603566
Market cap523mUSD
Sep 30, Last price
10.24CNY
Name
Pulike Biological Engineering Inc
Chart & performance
P/E
18.93
P/S
3.21
EPS
0.54
Div yield, %
5.86%
Shrs. gr., 5y
1.61%
Rev. gr., 5y
3.26%
Revenues
1.09b
+4.54%
Net income
185m
+99.33%
CFO
356m
+32.57%
Dividend
Jun 16, 20260.4 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Pulike Biological Engineering, Inc. focuses on the entire lifecycle of animal health products, from scientific innovation and manufacturing to market distribution. The company provides a range of veterinary biologicals and pharmaceuticals, including specialized vaccines, antibodies, and medications developed for swine and poultry. Additionally, it produces various disinfectants. Its corporate headquarters are located in Luoyang, China.
Key people
Dechao Qin
Vice Chairman of the Board · since 2020
Lianfeng Pei
Chief Financial Officer, Director · since 2023
Wei Hu
General Manager, Director · since 2020
Bing Han
Deputy General Manager · since 2023
Kegong Tian
Deputy General Manager
Rui Zhao
Secretary of the Board, Director · since 2023
Yongjun Song
Deputy General Manager, Director · since 2016
Xuke Zhang
Chairman of the Board
Yongchang Cao
Independent Director · since 2023
Chuduan Wang
Independent Director · since 2023
Xiansheng Zhang
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||